Menu Close

Pipeline

Bar graph showing progress of three programs

NCT10004

Potential first-in-class, once-a-day, oral treatment for refractory epilepsy. NCT10004 is being developed as a first line treatment for genetic epilepsy syndromes.

  • Activity in multiple seizure models
  • Expected to enter clinical trials in Q12020

GABAA α2/α3 Program

An α2/α3 selective candidate for chronic pain will be discovered through lead optimization enabled by a novel hit and new GABAA structural information.

GABAA α4β3δ Program

An α4β3δ selective candidate for genetic epilepsy syndromes will be discovered through lead optimization enabled by novel hits.